Stocks in play: Oncolytics Biotech Inc

Today announces recent operational highlights and financial results for the second quarter ended June 30, 2022. Highlights include; achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients; clinical biomarker data show pelareorep remodeling tumor microenvironments to improve prognosis and decrease the risk of recurrence in HR+/HER2- breast cancer patients. Cash and cash equivalents of 33.7 million (CAD) provides the projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer. Oncolytics Biotech Inc shares T.ONC are trading down one cent at $1.66.

Read:

• Mega Grocery Store Chains Listening to Customers’ Demands for Nutritious, Clean-Label Foods

• Innovative Food Stocks Responding to Conflict-, and Drought-Driven Food Supply Shocks

• Crypto Miners Finding Success While Shifting Towards Environmentally Sustainable Operations

• New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors

• As a Major Social Media Shuffle Looms, Uptake and Value of Dogecoin (DOGE) Surges